RTI Stock Overview
A biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Revance Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.50 |
| 52 Week High | US$8.40 |
| 52 Week Low | US$2.18 |
| Beta | 0.95 |
| 11 Month Change | -20.09% |
| 3 Month Change | -39.13% |
| 1 Year Change | -45.74% |
| 33 Year Change | -69.03% |
| 5 Year Change | -78.26% |
| Change since IPO | -81.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| RTI | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.9% | 1.4% | 0.8% |
| 1Y | -45.7% | -18.4% | 9.1% |
Return vs Industry: RTI underperformed the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: RTI underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| RTI volatility | |
|---|---|
| RTI Average Weekly Movement | 11.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RTI's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RTI's weekly volatility has decreased from 22% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 597 | Mark Foley | www.revance.com |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage.
Revance Therapeutics, Inc. Fundamentals Summary
| RTI fundamental statistics | |
|---|---|
| Market cap | €372.82m |
| Earnings (TTM) | -€288.71m |
| Revenue (TTM) | €244.82m |
1.6x
P/S Ratio-1.3x
P/E RatioIs RTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RTI income statement (TTM) | |
|---|---|
| Revenue | US$256.95m |
| Cost of Revenue | US$153.26m |
| Gross Profit | US$103.69m |
| Other Expenses | US$406.70m |
| Earnings | -US$303.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.89 |
| Gross Margin | 40.35% |
| Net Profit Margin | -117.93% |
| Debt/Equity Ratio | -264.5% |
How did RTI perform over the long term?
See historical performance and comparison